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INTRODUCTION:
Sertoli-Leydig cell tumor (SLCT) is a rare ovarian tumor
that belongs to the group of sex-cord stromal tumors.
These constitute less than 0.5% of ovarian tumors.Most
tumors are seen during the second and third decades of
life1. These tumors are characterized by the presence of
testicular structures that produce androgens. Hence, many
patients have symptoms of virilization depending on the
quantity of androgen production. The second characteristic
feature of these tumors is the degree of differentiation
of structures in them. The presence of these structures
determines whether the tumors are benign or malignant.2
Most of these tumors are unilateral and diagnosed in
stage I, so conservative surgery in a young patient is an
appropriate treatment. There have also been case reports
of successful laparoscopic management of the
tumors.Adjuvant chemotherapy is considered for patients
who have poor prognostic factors.3
We present the case report of a young woman with Sertoli-
leydig cell tumor of intermediate type limited to only
one ovary.
CASE REPORT:
A 32-year-old nulliparous woman presented in
Gynaecology outpatient department, with complain of
secondary amenorrhea of 8 months duration preceded
by menstrual irregularity (Oligomenorrhea) for last 1
year. She had also noticed a change in her voice and hair
growth on her face. She was married for the last 2.5 years
and had history of primary infertility. She denied any
history of anorexia, weight loss, increased libido, or
breast recession. Her medical and family history was
unremarkable.
Her general physical examination was normal. Her height
was 5 feet 4 inches and weight was 66 kg. Perineal
inspection revealed mild clitoral hypertrophy. Vaginal
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examination revealed a firm and mobile mass of 6x6 cm
in the left adnexa. Transvaginal ultrasound revealed a
5cm by 6cm solid cystic mass in the left ovary. The right
ovary and the uterus were normal. Both adrenal glands
were also normal. MRI confirmed the findings of
ultrasound with no metastatic deposits. Her thyroid
profile, S.FSH levels were normal but raised S.LH. A
hormonal profile in blood indicated excessive androgenic
activity in the form of elevated serum testosterone level
(475.5 mg/dL; normal, 8.4-48.1 mg/dl), serum
androstenedione (6.22 mg/dl: normal, 0.3-3.3mg/dl),
serum free androgen index (56.6%; normal, 0.51- 6.53%).
However, levels of sex hormone binding globulin,
dehydroepiandrosterone sulfate (DHEAS), CA 125, and
alpha-fetoprotein (AFP) were normal. On the basis of
these findings, a provisional diagnosis of androgen-
producing ovarian tumor was made. Exploratory
laparotomy was performed. Operative findings showed
replacement of left ovary by a 5 x 6-cm solid cystic,
grey-white, smooth-surface intact mass. No deposits were
found in the abdominal cavity and para-aortic lymph
nodes were not enlarged. The right ovary was normal.
Left oophrectomy was done. Peritoneal washings were
sent for cytological examination. An omental biopsy was
also taken. However, lymph node dissection was not
done. Patient had an uneventful recovery. The
histopathology report showed an intermediate (borderline)
type of sertoli-leydig cell tumor. Immunohistochemical
staining showed that tumor was positive for inhibin and
cytokeratin. Peritoneal washing did not reveal any
abnormal cells.  No chemotherapy was done.
During 6 months of follow-up, she started having normal
periods, with resolution of her virilization symptoms.
Repeat testosterone levels on follow-up were within
normal range.
ABSTRACT:
Sertoli-Leydig cell tumor (SLCT) of ovary is an unusual neoplasm that belongs to a group of sex cord-stromal tumors of ovary. It accounts for less
than 0.5% of all primary ovarian neoplasms. We report a case of primary intermediate ovarian Sertoli-Leydig cell tumor (SLCT) involving the left
ovary in a 32-year-old nulliparous woman who presented with history of secondary amenorrhea for 8 months, hirsutism, and voice changes.
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Fig: 1
Gross appearance of Sertoli-Leydig cell tumor
produce and release a male sex hormone which may
cause the development of male physical characteristics
including facial hair and a deep voice7. Similar features
were present in this case also.
In our patient, ovarian tumor was diagnosed on ultrasound.
Hormone assessment was done due to development of
male hormone symptoms.In the surgical treatment of
SLCTs it is necessary to adopt common guidelines, and
evenly define the steps that the patient should be
submitted. Laparotomy was done in this patient;
howeverthere have also been case reports of successful
laparoscopic management of these tumors.3 Different
steps that are usually used for oncological ovarian cancer
staging are not always performed. Conservative and
fertility sparing surgery is commonly accepted, and even
preferred due to the young age of patients as done in our
patient and another study.8 The important prognostic
factors in these tumors are their stage and degree of
differentiation. In a review of 207 cases by Young and
Scully in 1985 1 all well-differentiated tumors were
benign, whereas 11% of tumors with intermediate
differentiation, 59% of tumors with poor differentiation,
and 19% of those with heterologous elements were
malignant. In the present case report histopathology
report showed intermediate differentiation which has a
good prognosis. Of various immunohistochemical stains
applied, Inhibin and cytokeratins were positive in the
histopathology report of this patient SLCT, as same
results were found in another study.4
In this patient as tumor was of early stage and of
intermediate type so chemotherapy was not
recommendedin contrast to a study 9 whereincomplete
staging of the tumor and the presence of heterologous
elements on histopathology favors for chemotherapy.
The malignancy rate in tumors with heterologous elements
is 15% to 20%. Adjuvant chemotherapy in stage I is
given to those patients who have poorly differentiated
SLCT or SLCT with heterologous elements or a metastatic
tumor of any histologic type. The BEP (Bleomycin,
Etoposide, Cisplatin) regimen is a comparatively safe
chemotherapeutic regimen because it does not affect the
fertility status of the patient.10During her 6 months follow
up, patient had resumed normal menstrual cycles and her
voice also became feminine as another study concluded
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DISCUSSION:
Sertoli-Leydig cell tumors are rare of all ovarian tumors,
as in one study of Pakistan 4 only 7% of sex cord stromal
tumors were SLCT. While they can be found in women
of all age groups, they are most common in young women.
 Our patient presented at young age in contrast to two
studies that reported a teenage girl and a postmenopausal
woman.5,6 Virilization in females can occur based on
ovarian or adrenal pathology. In terms of ovarian-based
female virilization, Sertoli-Leydig cell ovarian tumors
that feminine characteristics return after surgery, but
manifestat ions of  masculinizat ion disappear
more slowly. 9
In conclusion, SLCT is a rare ovarian sex-cord tumor
that usually occurs unilaterally. SLCT should always be
considered in a young female patient who has symptoms
of virilization and an ovarian mass on examination or
investigation.Management depends on the histopathology
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In conclusion, SLCT is a rare ovarian sex-cord tumor
that usually occurs unilaterally. SLCT should always be
considered in a young female patient who has symptoms
of virilization and an ovarian mass on examination or
investigation.Ma agement depends on the histopath logy
of the tum r. Intermediately differe tiated tumors need
an individualized appro ch.
